Security
AARD · Aardvark Therapeutics, Inc.
AARDNASDAQCommon stockCurrentCIK 1774857Updated Sep 27, 2026
AARD price & chart
Loading TradingView…
NASDAQ:AARD on TradingView ↗About the company
Aardvark is a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of Prader-Willi Syndrome (PWS) and metabolic diseases. Hunger, which is the discomfort from not having eaten recently, is a distinct neural signaling pathway separate from appetite, the reward-seeking desire for food. Our programs explore therapeutic applications in hunger-associated
In the news
Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors – AARD ↗
Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors - AARD ↗
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit ↗
Recent filings
4 filing
4 filing
Submission of Matters to a Vote of Security Holders
Items 5.07
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| ASSETS | ||
| AssetsUSD | 117,181,000Source | 77,507,000Source |
| Current assets: | ||
| Cash and Cash Equivalents, at Carrying ValueUSD | 47,051,000Source | 61,641,000Source |
| Assets, CurrentUSD | 111,886,000Source | 74,137,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,859,000Source | 474,000Source |
| Operating Lease, Right-of-Use AssetUSD | 355,000Source | 735,000Source |
| Other Assets, NoncurrentUSD | 4,940,000Source | 2,635,000Source |
| LIABILITIES AND EQUITY | ||
| LiabilitiesUSD | 10,548,000Source | 5,394,000Source |
| Stockholders’ equity: | ||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 0Source | 0Source |
| Retained Earnings (Accumulated Deficit)USD | -115,918,000Source | -58,327,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 81,000Source | 0Source |
| Stockholders' Equity Attributable to ParentUSD | 106,633,000Source | -54,643,000Source |
| Additional Paid in Capital, Common StockUSD | 222,470,000Source | 3,684,000Source |
| Liabilities and EquityUSD | 117,181,000Source | 77,507,000Source |
| Current liabilities: | ||
| Liabilities, CurrentUSD | 10,548,000Source | 4,927,000Source |
| Operating Lease, Liability, CurrentUSD | 441,000Source | 338,000Source |
| Accounts Payable, CurrentUSD | 2,072,000Source | 2,298,000Source |
| Operating Lease, Liability, NoncurrentUSD | 0Source | 441,000Source |
| Other Liabilities, NoncurrentUSD | 0Source | 26,000Source |
| Additional Financial Items | ||
| Accrued Liabilities, CurrentUSD | 8,035,000Source | 2,291,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 110,000,000Source | — |
| Short-term InvestmentsUSD | 62,976,000Source | 12,022,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Cash flows from operating activities: | ||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation, Depletion and AmortizationUSD | 36,000Source | 16,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 3,948,000Source | 439,000Source |
| Changes in operating assets and liabilities: | ||
| Increase (Decrease) in Accounts PayableUSD | 239,000Source | 798,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -54,172,000Source | -18,087,000Source |
| Cash flows from investing activities: | ||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -49,667,000Source | -11,998,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 95,000Source | 109,000Source |
| Cash flows from financing activities: | ||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 89,249,000Source | 81,991,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 47,051,000Source | 61,641,000Source |
| Additional Financial Items | ||
| Share-based Payment Arrangement, ExpenseUSD | 3,948,000Source | 439,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 110,000,000Source | — |
| General and Administrative ExpenseUSD | 13,789,000Source | 5,305,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -57,591,000Source | -20,588,000Source |
| Nonoperating Income (Expense)USD | 5,134,000Source | 2,197,000Source |
| Operating ExpensesUSD | 62,725,000Source | 22,785,000Source |
| Operating Lease, ExpenseUSD | 900,000Source | — |
| Payments of Financing CostsUSD | 0Source | 1,193,000Source |
| Proceeds from Issuance of Common StockUSD | 195,000Source | 0Source |
| Proceeds from Stock Options ExercisedUSD | 366,000Source | 332,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 0Source | — |
| Unrealized Gain (Loss) on InvestmentsUSD | -5,000Source | -217,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Operating Income (Loss)USD | -62,725,000Source | -22,785,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -57,591,000Source | -20,588,000Source |
| Earnings Per Share, BasicUSD per share | -2.93Source | -5.15Source |
| Earnings Per Share, DilutedUSD per share | -2.93Source | -5.15Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 19,624,626Source | 3,996,376Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 19,624,626Source | 3,996,376Source |
| Additional Financial Items | ||
| General and Administrative ExpenseUSD | 13,789,000Source | 5,305,000Source |
| Labor and Related ExpenseUSD | 11,965,000Source | 4,272,000Source |
| Nonoperating Income (Expense)USD | 5,134,000Source | 2,197,000Source |
| Operating ExpensesUSD | 62,725,000Source | 22,785,000Source |
| Operating Lease, ExpenseUSD | 900,000Source | — |
| Research and Development ExpenseUSD | 48,936,000Source | 17,363,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 0Source | — |
Filing attachments
ck0001774857-ex99_1.htm · 8-K · 2026-08-11
EX-99.1 2 ck0001774857-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates Assessing unblinded Phase 3 HERO and OLE data for ARD-101 in PWS in the third quarter of 2026 to support an informed determination of next steps Remains in active discussions with the FDA to support resolution of the clinical hold for ARD-101 program $73.9 million in cash, cash equivalents and short-term investments as of June 3…
Read attachment ↗ck0001774857-ex99_1.htm · 8-K · 2026-05-14
EX-99.1 2 ck0001774857-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold SAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that the U.…
Read attachment ↗ck0001774857-ex99_1.htm · 8-K · 2026-05-07
EX-99.1 2 ck0001774857-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates ARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026 $91.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, supports projected operations into mid-2027 SAN DIEGO, May 7, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD),…
Read attachment ↗ck0001774857-ex99_1.htm · 8-K · 2026-03-23
EX-99.1 2 ck0001774857-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates Voluntary pause of the Phase 3 HERO and OLE trials evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi Syndrome, further guidance on the program expected in Q2 2026 ARD-201 obesity program, including POWER and STRENGTH trials, on voluntary pause pending next steps with ARD-101; furth…
Read attachment ↗